CEL-SCI Expands H1N1 Flu Virus Work
CEL-SCI has two on-going research programs directed towards the H1N1 virus. The first one is directed against a future mutated form of the virus. It is the fear of many experts that the H1N1 virus will continue to mutate and "swap genes" to become more lethal. CEL-SCI is focused on creating a treatment/vaccine against such a virus by combining non-changing parts of the H1N1 virus, the Avian Flu virus and the Spanish Flu virus. When a new virus surfaces, this treatment/vaccine is expected to provide an important cornerstone for the fight against the virus.
The second program is directed at helping very sick patients infected with the current form of H1N1. CEL-SCI expects to give updated communication on that program within the next month.
CEL-SCI's L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) technology allows the Company to direct an immune response against a specific disease epitope, in this case non-changing regions of H1N1, Avian Flu and the Spanish Flu. This makes it possible to 1) program the intended immune response and 2) avoid the administration of regions of the H1N1, and other viruses, that may exacerbate the problem of cytokine storm. Cytokine storm is very much involved in the death of many H1N1 patients.
The L.E.A.P.S. technology combines a small peptide that activates the immune system with a small peptide from a disease-related protein, such as the H1N1 hemagglutinin molecule, to make a vaccine that induces a defined immune response. Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which has previously demonstrated the ability to induce and elicit protective immunity and antigen specific antibody production in animal models. In CEL-SCI's L.E.A.P.S. swine flu vaccine the TCBLs will be coupled to three different highly conserved protective epitopes from three different essential proteins common to all influenza A virus strains.
L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to prevent and treat swine and other influenzas using its L.E.A.P.S. technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Source: CEL-SCI Corporation